| 1 | The need for personalization when sharing results of amyloid imaging for Alzheimer’s disease: Insights from a randomized experimental study | 2.1 | 1 | Citations (PDF) |
| 2 | Neuroinflammation in Alzheimer disease | 53.8 | 242 | Citations (PDF) |
| 3 | Tract-specific white matter hyperintensities and neuropsychiatric syndromes: a multicentre memory clinic study | 6.3 | 3 | Citations (PDF) |
| 4 | Zooming in on brain inflammation in Alzheimer’s disease | 8.4 | 2 | Citations (PDF) |
| 5 | Prevalence of Pathogenic Variants and Eligibility Criteria for Genetic Testing in Patients Who Visit a Memory Clinic | 1.0 | 4 | Citations (PDF) |
| 6 | Needs expressed by people with subjective cognitive decline during amyloid PET disclosure consultations: An observational study | 2.1 | 1 | Citations (PDF) |
| 7 | Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts | 1.9 | 2 | Citations (PDF) |
| 8 | Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus | 2.8 | 6 | Citations (PDF) |
| 9 | Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure | 3.6 | 1 | Citations (PDF) |
| 10 | SCD‐plus features and AD biomarkers in cognitively unimpaired samples: A meta‐analytic approach for nine cohort studies | 0.5 | 6 | Citations (PDF) |
| 11 | Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry) | 2.8 | 0 | Citations (PDF) |
| 12 | TREM2 risk variants and associated endophenotypes in alzheimer’s disease | 6.6 | 9 | Citations (PDF) |
| 13 | Exploring interdisciplinary perspectives on the implementation of
personalized medicine
and
patient-orchestrated care
in Alzheimer's disease: A qualitative study within the ABOARD research project | 2.6 | 0 | Citations (PDF) |
| 14 | Dynamic PET imaging in patients with unilateral carotid occlusion shows lateralized cerebral hypoperfusion, but no amyloid binding | 2.6 | 0 | Citations (PDF) |
| 15 | Individualized lesion-symptom mapping using explainable artificial intelligence for the cognitive impact of white matter hyperintensities | 3.3 | 1 | Citations (PDF) |
| 16 | Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease | 1.0 | 3 | Citations (PDF) |
| 17 | Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies | 2.8 | 11 | Citations (PDF) |
| 18 | Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study | 0.5 | 10 | Citations (PDF) |
| 19 | A novel approach to resilience and its links with education and Alzheimer's disease genetics | 0.5 | 1 | Citations (PDF) |
| 20 | Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum | 6.6 | 2 | Citations (PDF) |
| 21 | CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer’s disease patients | 6.6 | 1 | Citations (PDF) |
| 22 | Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives | 0.5 | 3 | Citations (PDF) |
| 23 | Small vessel disease burden and functional brain connectivity in mild cognitive impairment | 1.0 | 2 | Citations (PDF) |
| 24 | Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups | 1.0 | 26 | Citations (PDF) |
| 25 | Contributions of amyloid beta and cerebral small vessel disease in clinical decline | 0.5 | 7 | Citations (PDF) |
| 26 | Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles | 14.5 | 148 | Citations (PDF) |
| 27 | Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function | 2.6 | 6 | Citations (PDF) |
| 28 | Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis | 5.2 | 25 | Citations (PDF) |
| 29 | Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts | 0.5 | 35 | Citations (PDF) |
| 30 | Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART‐MR Study | 4.0 | 8 | Citations (PDF) |
| 31 | Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementiaBrain, 2024, 147, 3522-3533 | 8.4 | 4 | Citations (PDF) |
| 32 | Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study | 0.5 | 25 | Citations (PDF) |
| 33 | Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia | 1.0 | 17 | Citations (PDF) |
| 34 | Performance evaluation of neural networks and support-vector regression for lesion-symptom mapping in cerebral small vessel disease | 1.0 | 0 | Citations (PDF) |
| 35 | Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessmentBrain, 2024, 147, 4265-4279 | 8.4 | 10 | Citations (PDF) |
| 36 | The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study | 6.6 | 4 | Citations (PDF) |
| 37 | CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals | 14.1 | 4 | Citations (PDF) |
| 38 | Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting | 2.5 | 9 | Citations (PDF) |
| 39 | Markers of amyloid-β deposition and burden of enlarged perivascular spaces in patients with cognitive impairment and small vessel disease | 2.6 | 1 | Citations (PDF) |
| 40 | Amyloid‐positivity is characterized by decline in semantic fluency: An in‐depth investigation of verbal fluency trajectories, item‐level characteristics and its prognostic value in patients with subjective cognitive decline | 0.5 | 1 | Citations (PDF) |
| 41 | Novel microglial markers that are specifically increased in early clinical AD stages | 0.5 | 0 | Citations (PDF) |
| 42 | Passively collected smartphone behaviour as a reliable and feasible measure for global cognition in Alzheimer’s Disease | 0.5 | 0 | Citations (PDF) |
| 43 | Bridging the Gap between Cognition and Everyday Functioning: A linking Study in Amyloid Positive Participants | 0.5 | 0 | Citations (PDF) |
| 44 | Multi‐day at‐home assessments of speech acoustics in Dutch cognitively normal adults with‐and without AD pathology | 0.5 | 0 | Citations (PDF) |
| 45 | Long‐read sequencing reveals common structural variants as potential drivers of genetic rick for neurodegenerative diseases | 0.5 | 0 | Citations (PDF) |
| 46 | Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease | 0.5 | 0 | Citations (PDF) |
| 47 | Unravelling the role of subcortical brain volumes in the conversion to dementia: a multi‐cohort analysis | 0.5 | 0 | Citations (PDF) |
| 48 | The prevalence of tau‐PET positivity in aging and dementia | 0.5 | 0 | Citations (PDF) |
| 49 | Cognitive and physical activity are related to increased cognitive reserve in a large memory clinic cohort | 0.5 | 0 | Citations (PDF) |
| 50 | Participant recruitment strategies via the Dutch Brain Research Registry: a comparison of effectiveness and efficiency of different strategies for the multi‐domain lifestyle intervention trial FINGER‐NL | 0.5 | 0 | Citations (PDF) |
| 51 | Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project | 2.4 | 22 | Citations (PDF) |
| 52 | European consensus for the diagnosis of MCI and mild dementia: Preparatory phase | 0.5 | 25 | Citations (PDF) |
| 53 | Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals | 4.7 | 4 | Citations (PDF) |
| 54 | Strategic white matter hyperintensity locations for cognitive impairment: A multicenter lesion‐symptom mapping study in 3525 memory clinic patients | 0.5 | 50 | Citations (PDF) |
| 55 | Dementia prevention in memory clinics: recommendations from the European task force for brain health services | 7.0 | 124 | Citations (PDF) |
| 56 | C1q is increased in cerebrospinal fluid‐derived extracellular vesicles in Alzheimer's disease: A multi‐cohort proteomics and immuno‐assay validation study | 0.5 | 36 | Citations (PDF) |
| 57 | Motivations of patients and their care partners for visiting a memory clinic. A qualitative study | 2.1 | 9 | Citations (PDF) |
| 58 | Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET studyBrain, 2023, 146, 4040-4054 | 8.4 | 51 | Citations (PDF) |
| 59 | Determinants of quality of life in family caregivers in MCI: a comparison with mild dementia | 2.9 | 2 | Citations (PDF) |
| 60 | Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia | 6.7 | 21 | Citations (PDF) |
| 61 | Psychometric characteristics of the Amsterdam instrumental activities of daily living questionnaire in healthy individuals and NIA‐AA stages of preclinical Alzheimer’s Disease | 0.5 | 0 | Citations (PDF) |
| 62 | Facilitating clinical use of the Amsterdam instrumental activities of daily living questionnaire: Dutch normative data and clinical cutoff values | 0.5 | 0 | Citations (PDF) |
| 63 | What does heritability of Alzheimer’s disease represent? | 2.3 | 40 | Citations (PDF) |
| 64 | Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease | 9.0 | 31 | Citations (PDF) |
| 65 | Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study | 2.5 | 4 | Citations (PDF) |
| 66 | Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by
HLA-DRB1*04
subtypes | 7.5 | 39 | Citations (PDF) |
| 67 | Performance of a [
18
F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies | 1.0 | 17 | Citations (PDF) |
| 68 | CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease | 13.7 | 53 | Citations (PDF) |
| 69 | Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline | 2.7 | 2 | Citations (PDF) |
| 70 | Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation | 2.5 | 8 | Citations (PDF) |
| 71 | Passive logging of smartphone interactions as a feasible and reliable measure to monitor everyday cognition in Alzheimer’s Disease | 0.5 | 1 | Citations (PDF) |
| 72 | Dissecting the shared genetic basis of Alzheimer’s disease and hippocampal volumes | 0.5 | 0 | Citations (PDF) |
| 73 | ABOARD Cohort; a national initiative to involve citizens in AD research | 0.5 | 0 | Citations (PDF) |
| 74 | Predicting Sojourn Times across Dementia Disease Stages, Institutionalization, and Mortality | 0.5 | 1 | Citations (PDF) |
| 75 | Replication of HLA‐DRB1*04:04 allele subtype protective effect against Alzheimer’s Disease in cognitively healthy centenarians using long‐read sequencing | 0.5 | 0 | Citations (PDF) |
| 76 | Identifying Cognitive Resilience Related Genes Among Genetic Risk Loci of Alzheimer’s Disease | 0.5 | 2 | Citations (PDF) |
| 77 | The Amsterdam Approach: optimizing care and research | 0.5 | 1 | Citations (PDF) |
| 78 | The association between AD biomarkers and neuropsychiatric symptoms in subjective cognitive decline; the SCIENCe project | 0.5 | 0 | Citations (PDF) |
| 79 | Can escapees of familial AD help identify protective factors? A case report of an extremely resilient PSEN1 carrier | 0.5 | 0 | Citations (PDF) |
| 80 | Data driven criteria for genetic testing result in an efficient selection of patients with genetic dementia in a clinical setting | 0.5 | 0 | Citations (PDF) |
| 81 | Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach | 0.5 | 0 | Citations (PDF) |
| 82 | Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning | 0.5 | 1 | Citations (PDF) |
| 83 | Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort | 0.5 | 1 | Citations (PDF) |
| 84 | Reduced visual associative learning is linked to Alzheimer’s disease pathology | 0.5 | 0 | Citations (PDF) |
| 85 | Facilitating Clinical Use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative Data and Diagnostic Cutoff Values | 0.5 | 0 | Citations (PDF) |
| 86 | The prevalence of young‐onset dementia in the Netherlands: a prospective study | 0.5 | 0 | Citations (PDF) |
| 87 | Blood-based biomarkers for Alzheimer's disease: towards clinical implementation | 17.9 | 771 | Citations (PDF) |
| 88 | Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown | 2.6 | 11 | Citations (PDF) |
| 89 | Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report | 4.0 | 7 | Citations (PDF) |
| 90 | Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease | 5.5 | 16 | Citations (PDF) |
| 91 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum | 17.6 | 227 | Citations (PDF) |
| 92 | Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies | 1.0 | 24 | Citations (PDF) |
| 93 | Gut Microbiota Composition Is Related to AD Pathology | 4.9 | 163 | Citations (PDF) |
| 94 | Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment | 1.7 | 3 | Citations (PDF) |
| 95 | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping | 6.6 | 16 | Citations (PDF) |
| 96 | Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline | 1.0 | 66 | Citations (PDF) |
| 97 | Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review | 6.6 | 49 | Citations (PDF) |
| 98 | Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline | 3.6 | 17 | Citations (PDF) |
| 99 | Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study | 1.0 | 4 | Citations (PDF) |
| 100 | Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI | 1.0 | 0 | Citations (PDF) |
| 101 | A comparison of two approaches for modeling dementia progression in a changing patient context | 2.2 | 4 | Citations (PDF) |
| 102 | Cerebrovascular disease in suspected non‐Alzheimer's pathophysiology and cognitive decline over time | 3.5 | 14 | Citations (PDF) |
| 103 | New insights into the genetic etiology of Alzheimer’s disease and related dementias | 25.2 | 2,005 | Citations (PDF) |
| 104 | Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis | 2.6 | 11 | Citations (PDF) |
| 105 | Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia | 2.5 | 60 | Citations (PDF) |
| 106 | Subjective cognitive decline and self‐reported sleep problems: The SCIENCe project | 2.5 | 10 | Citations (PDF) |
| 107 | Determining the Minimal Important Change of Everyday Functioning in Dementia | 1.0 | 14 | Citations (PDF) |
| 108 | Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease | 17.6 | 77 | Citations (PDF) |
| 109 | Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease | 3.6 | 11 | Citations (PDF) |
| 110 | Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β Accumulation and Neurodegeneration in Alzheimer’s Disease? | 2.6 | 3 | Citations (PDF) |
| 111 | Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE) | 17.6 | 70 | Citations (PDF) |
| 112 | Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease | 6.6 | 10 | Citations (PDF) |
| 113 | Development and design of a diagnostic report to support communication in dementia: Co‐creation with patients and care partners | 2.5 | 7 | Citations (PDF) |
| 114 | Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals | 5.5 | 13 | Citations (PDF) |
| 115 | Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers | 9.2 | 112 | Citations (PDF) |
| 116 | Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline | 33.0 | 362 | Citations (PDF) |
| 117 | CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels | 14.5 | 69 | Citations (PDF) |
| 118 | Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease | 25.2 | 183 | Citations (PDF) |
| 119 | Differential responsiveness of outcome measures according to biomarker inclusion criteria: implications for trial design | 0.5 | 0 | Citations (PDF) |
| 120 | Memory clinic clinicians’ preferences and needs for communication with patients: A multi‐national survey study from EU‐FINGERS & LETHE projects | 0.5 | 0 | Citations (PDF) |
| 121 | The impact of COVID‐19 restrictions after one year on modifiable risk factors related to brain health in older adults in The Netherlands | 0.5 | 0 | Citations (PDF) |
| 122 | Teleneuropsychology in the memory clinic setting: evidence for reliability and usability of videoconference‐based neuropsychological testing | 0.5 | 2 | Citations (PDF) |
| 123 | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease | 0.5 | 0 | Citations (PDF) |
| 124 | Protective association of HLA‐DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences | 0.5 | 2 | Citations (PDF) |
| 125 | Subjective cognitive decline and clinical progression in the memory clinic: The value of longitudinal self‐ and informant‐report in the SCIENCe project | 0.5 | 0 | Citations (PDF) |
| 126 | How e‐solutions can help to improve the AD diagnostic pathway | 0.5 | 0 | Citations (PDF) |
| 127 | Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4 | 0.5 | 1 | Citations (PDF) |
| 128 | Precision estimates of Relative and Absolute Cerebral Blood Flow in Alzheimer’s disease and Cognitively Normal individuals | 0.5 | 0 | Citations (PDF) |
| 129 | Optimizing cCOG, a web‐based tool, to detect dementia with Lewy Bodies. | 0.5 | 1 | Citations (PDF) |
| 130 | Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study | 4.7 | 11 | Citations (PDF) |
| 131 | Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment | 6.2 | 34 | Citations (PDF) |
| 132 | Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT | 4.8 | 12 | Citations (PDF) |
| 133 | Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score | 2.5 | 22 | Citations (PDF) |
| 134 | Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer’s disease | 3.3 | 73 | Citations (PDF) |
| 135 | Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies | 2.2 | 13 | Citations (PDF) |
| 136 | Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups | 3.3 | 24 | Citations (PDF) |
| 137 | Biomarker testing in MCI patients—deciding who to test | 6.6 | 7 | Citations (PDF) |
| 138 | Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts | 6.6 | 29 | Citations (PDF) |
| 139 | Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old | 3.8 | 14 | Citations (PDF) |
| 140 | Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies | 2.2 | 2 | Citations (PDF) |
| 141 | Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results | 6.6 | 36 | Citations (PDF) |
| 142 | The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series | 2.6 | 18 | Citations (PDF) |
| 143 | Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study | 10.3 | 163 | Citations (PDF) |
| 144 | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives | 5.5 | 29 | Citations (PDF) |
| 145 | Alzheimer's disease | 62.3 | 4,252 | Citations (PDF) |
| 146 | Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease | 4.9 | 44 | Citations (PDF) |
| 147 | Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity | 1.0 | 71 | Citations (PDF) |
| 148 | Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset | 2.6 | 16 | Citations (PDF) |
| 149 | Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease | 3.4 | 69 | Citations (PDF) |
| 150 | Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores | 13.7 | 272 | Citations (PDF) |
| 151 | Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies | 1.0 | 90 | Citations (PDF) |
| 152 | Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status | 6.6 | 33 | Citations (PDF) |
| 153 | Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods | 1.0 | 78 | Citations (PDF) |
| 154 | The natural history of primary progressive aphasia: beyond aphasia | 3.4 | 45 | Citations (PDF) |
| 155 | [
18
F]Flortaucipir PET Across Various
MAPT
Mutations in Presymptomatic and Symptomatic Carriers | 1.0 | 23 | Citations (PDF) |
| 156 | Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies | 2.6 | 22 | Citations (PDF) |
| 157 | Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum | 1.0 | 99 | Citations (PDF) |
| 158 | Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints | 2.6 | 7 | Citations (PDF) |
| 159 | Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics | 2.6 | 6 | Citations (PDF) |
| 160 | Global Prevalence of Young-Onset Dementia | 17.6 | 319 | Citations (PDF) |
| 161 | A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer’s Disease Research | 2.6 | 4 | Citations (PDF) |
| 162 | Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions | 5.2 | 18 | Citations (PDF) |
| 163 | Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia | 3.4 | 19 | Citations (PDF) |
| 164 | BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project | 3.4 | 10 | Citations (PDF) |
| 165 | Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status | 2.5 | 47 | Citations (PDF) |
| 166 | Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis? | 4.8 | 27 | Citations (PDF) |
| 167 | Differential trajectories of hypometabolism across cognitively-defined Alzheimer’s disease subgroups | 3.3 | 16 | Citations (PDF) |
| 168 | The Cognitive Online Self‐Test Amsterdam (COST‐A): Establishing norm scores in a community‐dwelling population | 2.5 | 7 | Citations (PDF) |
| 169 | Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum | 3.5 | 34 | Citations (PDF) |
| 170 | Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 | 6.6 | 89 | Citations (PDF) |
| 171 | Dementia risk communication. A user manual for Brain Health Services—part 3 of 6 | 6.6 | 45 | Citations (PDF) |
| 172 | Short Digital Spatial Memory Test Detects Impairment in Alzheimer’s Disease and Mild Cognitive Impairment | 2.5 | 11 | Citations (PDF) |
| 173 | Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 | 6.6 | 44 | Citations (PDF) |
| 174 | Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 | 6.6 | 72 | Citations (PDF) |
| 175 | Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 | 6.6 | 158 | Citations (PDF) |
| 176 | Psychosocial effects of Corona virus measures on (pre‐)dementia patients during 2nd lockdown | 0.5 | 0 | Citations (PDF) |
| 177 | Can we improve clinical trial design in Alzheimer’s disease? The participants point of view | 0.5 | 0 | Citations (PDF) |
| 178 | Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter? | 0.5 | 0 | Citations (PDF) |
| 179 | At‐home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Self‐Test Amsterdam (COST‐A) | 0.5 | 1 | Citations (PDF) |
| 180 | A stepwise approach towards diagnostic workup in dementia using online cognitive tools | 0.5 | 0 | Citations (PDF) |
| 181 | Everyday functioning in a community‐based volunteer population: Factors associated with concordance between participant and study partner—Report | 0.5 | 0 | Citations (PDF) |
| 182 | The (non)sense of diagnostic computer tools in memory clinics: An international survey assessing the views of clinicians, patients and caregivers | 0.5 | 1 | Citations (PDF) |
| 183 | Identifying and characterizing patterns of functional decline in memory clinic patients | 0.5 | 0 | Citations (PDF) |
| 184 | Subjective cognitive decline and self‐reported sleep at a memory clinic: The SCIENCe project | 0.5 | 0 | Citations (PDF) |
| 185 | The incidence of young onset dementia: A systematic review and meta‐analysis | 0.5 | 3 | Citations (PDF) |
| 186 | Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter? | 0.5 | 0 | Citations (PDF) |
| 187 | The Effect of Alzheimer’s Disease-Associated Genetic Variants on Longevity | 2.3 | 11 | Citations (PDF) |
| 188 | Study design of FINGER‐NL: A multidomain lifestyle intervention in Dutch older adults to prevent cognitive decline | 0.5 | 4 | Citations (PDF) |
| 189 | Young‐onset dementia in memory clinics in the Netherlands: PRECODE‐GP | 0.5 | 0 | Citations (PDF) |
| 190 | Test–retest repeatability of [<sup>18</sup>F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals | 4.7 | 31 | Citations (PDF) |
| 191 | Reply to “Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population” | 6.6 | 3 | Citations (PDF) |
| 192 | Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project | 2.9 | 30 | Citations (PDF) |
| 193 | Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia | 2.6 | 6 | Citations (PDF) |
| 194 | Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI | 6.6 | 21 | Citations (PDF) |
| 195 | Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships | 3.3 | 6 | Citations (PDF) |
| 196 | Why Is Amyloid-β PET Requested After Performing CSF Biomarkers? | 2.6 | 16 | Citations (PDF) |
| 197 | Brain amyloid β, cerebral small vessel disease, and cognition | 1.0 | 36 | Citations (PDF) |
| 198 | Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease | 5.2 | 55 | Citations (PDF) |
| 199 | Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study | 3.4 | 7 | Citations (PDF) |
| 200 | Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project | 6.6 | 28 | Citations (PDF) |
| 201 | Identifying a task-invariant cognitive reserve network using task potency | 4.4 | 17 | Citations (PDF) |
| 202 | Multitracer model for staging cortical amyloid deposition using PET imaging | 1.0 | 87 | Citations (PDF) |
| 203 | Latent atrophy factors related to phenotypical variants of posterior cortical atrophy | 1.0 | 32 | Citations (PDF) |
| 204 | The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries | 2.5 | 23 | Citations (PDF) |
| 205 | Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline | 2.4 | 60 | Citations (PDF) |
| 206 | Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid | 2.5 | 9 | Citations (PDF) |
| 207 | Prediction of poor clinical outcome in vascular cognitive impairment: TRACE‐VCI study | 2.5 | 5 | Citations (PDF) |
| 208 | cCOG: A web‐based cognitive test tool for detecting neurodegenerative disorders | 2.5 | 15 | Citations (PDF) |
| 209 | Cerebral blood flow and cognitive functioning in patients with disorders along the heart–brain axis | 4.8 | 22 | Citations (PDF) |
| 210 | Sex differences in CSF biomarkers vary by Alzheimer disease stage and
APOE
ε4 genotype | 1.0 | 75 | Citations (PDF) |
| 211 | Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies | 4.2 | 20 | Citations (PDF) |
| 212 | Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project | 2.5 | 13 | Citations (PDF) |
| 213 | A clinical-radiological framework of the right temporal variant of frontotemporal dementiaBrain, 2020, 143, 2831-2843 | 8.4 | 140 | Citations (PDF) |
| 214 | Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study | 3.3 | 17 | Citations (PDF) |
| 215 | Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort | 0.5 | 0 | Citations (PDF) |
| 216 | Determinants of cognitive decline and dementia in stage 2: The SCIENCe project | 0.5 | 0 | Citations (PDF) |
| 217 | Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid | 0.5 | 0 | Citations (PDF) |
| 218 | Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies | 0.5 | 3 | Citations (PDF) |
| 219 | Single‐cell profiling of circulating and brain‐resident immune cells in a mouse model for amyloidosis and in aged mice | 0.5 | 0 | Citations (PDF) |
| 220 | Amyloid‐β deposition in cognitively normal oldest‐old is associated with cortical thinning and faster memory decline | 0.5 | 1 | Citations (PDF) |
| 221 | Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure | 0.5 | 0 | Citations (PDF) |
| 222 | Dutch Brain Research Registry for online study participant recruitment: Design and first results | 0.5 | 0 | Citations (PDF) |
| 223 | Trajectories of decline in cognitively complex everyday activities across the Alzheimer’s disease continuum | 0.5 | 1 | Citations (PDF) |
| 224 | The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer’s disease | 0.5 | 2 | Citations (PDF) |
| 225 | A mixed‐methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living | 0.5 | 2 | Citations (PDF) |
| 226 | Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis | 0.5 | 1 | Citations (PDF) |
| 227 | Study partner‐ and self‐reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment | 0.5 | 1 | Citations (PDF) |
| 228 | Attitudes towards genetic susceptibility testing for Alzheimer’s disease dementia in cognitively normal adults: A survey study | 0.5 | 3 | Citations (PDF) |
| 229 | Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum | 6.6 | 39 | Citations (PDF) |
| 230 | CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers | 3.4 | 28 | Citations (PDF) |
| 231 | Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease | 5.5 | 44 | Citations (PDF) |
| 232 | Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia | 5.8 | 25 | Citations (PDF) |
| 233 | ATN classification and clinical progression in subjective cognitive decline | 1.0 | 171 | Citations (PDF) |
| 234 | Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach | 14.1 | 73 | Citations (PDF) |
| 235 | A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project | 4.5 | 26 | Citations (PDF) |
| 236 | PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment | 9.2 | 62 | Citations (PDF) |
| 237 | Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort | 2.6 | 24 | Citations (PDF) |
| 238 | Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project | 2.4 | 2 | Citations (PDF) |
| 239 | The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum | 1.7 | 63 | Citations (PDF) |
| 240 | Non‐memory cognitive symptom development in Alzheimer's disease | 3.5 | 10 | Citations (PDF) |
| 241 | CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer’s Disease | 2.6 | 36 | Citations (PDF) |
| 242 | The characterisation of subjective cognitive decline | 17.9 | 1,105 | Citations (PDF) |
| 243 | Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project | 3.4 | 46 | Citations (PDF) |
| 244 | Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project | 2.3 | 31 | Citations (PDF) |
| 245 | Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy | 2.3 | 14 | Citations (PDF) |
| 246 | Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease | 5.5 | 38 | Citations (PDF) |
| 247 | Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies | 6.6 | 31 | Citations (PDF) |
| 248 | Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer’s disease | 3.4 | 43 | Citations (PDF) |
| 249 | Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network | 5.5 | 21 | Citations (PDF) |
| 250 | Grey zone amyloid burden affects memory function: the SCIENCe project | 5.5 | 5 | Citations (PDF) |
| 251 | Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression | 4.6 | 62 | Citations (PDF) |
| 252 | What patients want to know, and what we actually tell them: The ABIDE project | 4.8 | 14 | Citations (PDF) |
| 253 | Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project | 2.4 | 19 | Citations (PDF) |
| 254 | Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease | 3.4 | 21 | Citations (PDF) |
| 255 | Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition | 3.6 | 16 | Citations (PDF) |
| 256 | Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology | 6.6 | 202 | Citations (PDF) |
| 257 | Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline | 6.6 | 52 | Citations (PDF) |
| 258 | LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project | 2.5 | 10 | Citations (PDF) |
| 259 | An Operational Definition of ‘Abnormal Cognition’ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons? | 2.6 | 5 | Citations (PDF) |
| 260 | Gray matter atrophy but not vascular brain injury is related to cognitive impairment in patients with heart failure | 2.2 | 1 | Citations (PDF) |
| 261 | Survival in memory clinic cohort is short, even in young-onset dementia | 6.3 | 38 | Citations (PDF) |
| 262 | Quantification of [
18
F]florbetapir: A test–retest tracer kinetic modelling study | 4.7 | 27 | Citations (PDF) |
| 263 | The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study | 2.4 | 29 | Citations (PDF) |
| 264 | Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review | 2.4 | 21 | Citations (PDF) |
| 265 | Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort | 2.6 | 27 | Citations (PDF) |
| 266 | Added value of amyloid PET in individualized risk predictions for MCI patients | 2.5 | 14 | Citations (PDF) |
| 267 | Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions | 3.4 | 68 | Citations (PDF) |
| 268 | Clinician‐patient communication during the diagnostic workup: The ABIDE project | 2.5 | 30 | Citations (PDF) |
| 269 | Pre-analytical stability of novel cerebrospinal fluid biomarkers | 1.5 | 17 | Citations (PDF) |
| 270 | Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset | 3.4 | 12 | Citations (PDF) |
| 271 | Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum | 6.6 | 45 | Citations (PDF) |
| 272 | Applying the ATN scheme in a memory clinic population | 1.0 | 64 | Citations (PDF) |
| 273 | VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies | 4.4 | 34 | Citations (PDF) |
| 274 | Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies | 6.6 | 41 | Citations (PDF) |
| 275 | Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics | 3.4 | 18 | Citations (PDF) |
| 276 | Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis | 6.0 | 40 | Citations (PDF) |
| 277 | ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics | 6.6 | 26 | Citations (PDF) |
| 278 | Discordant amyloid-β PET and CSF biomarkers and its clinical consequences | 6.6 | 51 | Citations (PDF) |
| 279 | Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study | 17.9 | 110 | Citations (PDF) |
| 280 | Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project | 4.0 | 51 | Citations (PDF) |
| 281 | Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project | 4.5 | 35 | Citations (PDF) |
| 282 | A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity | 9.2 | 112 | Citations (PDF) |
| 283 | Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease | 2.6 | 39 | Citations (PDF) |
| 284 | Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease | 3.5 | 51 | Citations (PDF) |
| 285 | Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression | 13.7 | 60 | Citations (PDF) |
| 286 | High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline | 1.7 | 38 | Citations (PDF) |
| 287 | Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project | 4.5 | 14 | Citations (PDF) |
| 288 | Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project | 6.6 | 36 | Citations (PDF) |
| 289 | Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study | 6.6 | 28 | Citations (PDF) |
| 290 | How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study | 2.6 | 6 | Citations (PDF) |
| 291 | ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly | 3.4 | 15 | Citations (PDF) |
| 292 | Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease | 3.3 | 34 | Citations (PDF) |
| 293 | Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment | 1.0 | 33 | Citations (PDF) |
| 294 | Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project | 3.4 | 56 | Citations (PDF) |
| 295 | Automatically computed rating scales from MRI for patients with cognitive disorders | 3.6 | 33 | Citations (PDF) |
| 296 | Detecting frontotemporal dementia syndromes using MRI biomarkers | 3.3 | 60 | Citations (PDF) |
| 297 | The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus | 2.6 | 20 | Citations (PDF) |
| 298 | IC‐P‐184: LONGITUDINAL DYNAMIC [18F]FLORTAUCIPIR PET REVEALS INCREASED EARLY STAGE TAU PATHOLOGY IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 299 | IC‐P‐187: [<sup>18</sup>F]FLORTAUCIPIR BINDING STRONGLY CORRELATES TO COGNITION ACROSS THE CLINICAL ALZHEIMER'S DISEASE CONTINUUM, INDEPENDENTLY OF CSF TAU | 0.5 | 0 | Citations (PDF) |
| 300 | F1‐04‐01: FREQUENCY OF SUBJECTIVE COGNITIVE DECLINE CRITERIA IN STAGE 2 OF THE NEW NIA‐AA FRAMEWORK: A MULTI‐COHORT STUDY FROM THE SUBJECTIVE COGNITIVE DECLINE PROFESSIONAL INTEREST AREA | 0.5 | 0 | Citations (PDF) |
| 301 | F1‐05‐01: LAB‐RELATED PRE‐ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS | 0.5 | 0 | Citations (PDF) |
| 302 | 6071Extent of hypertensive exposure in relation to vascular brain injury and cognitive impairment using heart-brain magnetic resonance imaging; The Heart-Brain Connection Study | 2.2 | 0 | Citations (PDF) |
| 303 | IC‐P‐100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 304 | F2‐01‐01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 305 | IC‐P‐025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 306 | TD‐P‐25: DEVELOPMENT AND USABILITY OF ADAPPT: AN ONLINE TOOL TO SUPPORT CLINICIANS, PATIENTS AND CAREGIVERS IN THE DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 307 | Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset | 3.4 | 52 | Citations (PDF) |
| 308 | IC‐02‐01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 309 | IC‐P‐076: FDG‐PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY‐DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 310 | IC‐P‐015: VOXEL‐BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i> | 0.5 | 0 | Citations (PDF) |
| 311 | High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study | 6.6 | 8 | Citations (PDF) |
| 312 | PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases | 6.6 | 27 | Citations (PDF) |
| 313 | Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease | 2.5 | 19 | Citations (PDF) |
| 314 | Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk | 25.2 | 2,202 | Citations (PDF) |
| 315 | Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease | 3.5 | 37 | Citations (PDF) |
| 316 | Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease | 3.4 | 7 | Citations (PDF) |
| 317 | Olfactory and gustatory functioning and food preferences of patients with Alzheimer’s disease and mild cognitive impairment compared to controls: the NUDAD project | 3.4 | 32 | Citations (PDF) |
| 318 | Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study | 2.1 | 15 | Citations (PDF) |
| 319 | Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease | 2.6 | 41 | Citations (PDF) |
| 320 | Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum | 1.0 | 113 | Citations (PDF) |
| 321 | Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study | 1.1 | 45 | Citations (PDF) |
| 322 | Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam | 2.8 | 23 | Citations (PDF) |
| 323 | Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction | 6.2 | 48 | Citations (PDF) |
| 324 | Single Subject Classification of Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging | 2.6 | 41 | Citations (PDF) |
| 325 | A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline | 3.5 | 46 | Citations (PDF) |
| 326 | Vascular cognitive impairment | 47.2 | 536 | Citations (PDF) |
| 327 | Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease | 1.2 | 51 | Citations (PDF) |
| 328 | Microbleeds are associated with depressive symptoms in Alzheimer's disease | 2.5 | 9 | Citations (PDF) |
| 329 | Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease | 6.6 | 28 | Citations (PDF) |
| 330 | Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory | 3.4 | 35 | Citations (PDF) |
| 331 | Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease | 3.4 | 64 | Citations (PDF) |
| 332 | Gray matter network measures are associated with cognitive decline in mild cognitive impairment | 3.4 | 49 | Citations (PDF) |
| 333 | Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia | 12.4 | 146 | Citations (PDF) |
| 334 | Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results | 1.1 | 169 | Citations (PDF) |
| 335 | Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease | 1.0 | 126 | Citations (PDF) |
| 336 | P3‐403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 337 | O1‐10‐06: CONTACTIN‐1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 338 | O1‐14‐04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION‐SYMPTOM MAPPING STUDY | 0.5 | 0 | Citations (PDF) |
| 339 | IC‐P‐111: [<sup>18</sup>F]FLORBETAPIR‐SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 340 | IC‐P‐222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM | 0.5 | 0 | Citations (PDF) |
| 341 | P2‐645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT | 0.5 | 1 | Citations (PDF) |
| 342 | P2‐350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX | 0.5 | 0 | Citations (PDF) |
| 343 | O2‐06‐03: AMYLOID‐β LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 344 | P2‐248: CONTACTIN‐2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT | 0.5 | 0 | Citations (PDF) |
| 345 | IC‐06‐05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 346 | P2‐228: PRE‐ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA | 0.5 | 0 | Citations (PDF) |
| 347 | IC‐P‐092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY | 0.5 | 1 | Citations (PDF) |
| 348 | P3‐134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES | 0.5 | 0 | Citations (PDF) |
| 349 | P4‐106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD | 0.5 | 1 | Citations (PDF) |
| 350 | P3‐438: PARAMETRIC IMAGING OF [<sup>18</sup>F]FLORBETAPIR: A TEST‐RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 351 | P3‐289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO‐SCD STUDY | 0.5 | 0 | Citations (PDF) |
| 352 | O2‐09‐03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NON‐ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT | 0.5 | 0 | Citations (PDF) |
| 353 | P2‐349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA | 0.5 | 0 | Citations (PDF) |
| 354 | P2‐352: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDE‐CLINICAL ENCOUNTER STUDY | 0.5 | 0 | Citations (PDF) |
| 355 | P2‐363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS | 0.5 | 0 | Citations (PDF) |
| 356 | P2‐134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASE‐CONTROL STUDIES | 0.5 | 0 | Citations (PDF) |
| 357 | P2‐360: [<sup>18</sup>F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM | 0.5 | 0 | Citations (PDF) |
| 358 | P3‐264: UNBIASED METHOD TO DETERMINE CUT‐POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION | 0.5 | 0 | Citations (PDF) |
| 359 | O2‐03‐03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY | 0.5 | 0 | Citations (PDF) |
| 360 | P4‐038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE? | 0.5 | 1 | Citations (PDF) |
| 361 | P2‐500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEART‐BRAIN AXIS | 0.5 | 0 | Citations (PDF) |
| 362 | O2‐06‐01: [<sup>18</sup>F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 363 | O5‐04‐01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE | 0.5 | 0 | Citations (PDF) |
| 364 | IC‐P‐093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS | 0.5 | 0 | Citations (PDF) |
| 365 | IC‐P‐033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 366 | P3‐342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI‐STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES | 0.5 | 0 | Citations (PDF) |
| 367 | IC‐P‐032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI‐STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES | 0.5 | 0 | Citations (PDF) |
| 368 | IC‐P‐192: DISEASE‐STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE | 0.5 | 2 | Citations (PDF) |
| 369 | F5‐05‐04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 370 | O3‐13‐06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS — THE ABIDE PROJECT | 0.5 | 0 | Citations (PDF) |
| 371 | O3‐14‐03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH | 0.5 | 0 | Citations (PDF) |
| 372 | O5‐01‐03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON‐NEGATIVE MATRIX FACTORIZATION | 0.5 | 0 | Citations (PDF) |
| 373 | P2‐284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY | 0.5 | 0 | Citations (PDF) |
| 374 | Diagnostiek van dementie: praktijkvariatie in Nederlandse geheugenpoliklinieken | 0.0 | 3 | Citations (PDF) |
| 375 | P3‐617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT? | 0.5 | 0 | Citations (PDF) |
| 376 | Diagnostiek van de ziekte van Alzheimer | 0.0 | 0 | Citations (PDF) |
| 377 | F4‐08‐01: PLASMA AMYLOID AS A PRE‐SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 378 | α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies | 4.6 | 97 | Citations (PDF) |
| 379 | Computer‐assisted prediction of clinical progression in the earliest stages of AD | 2.5 | 12 | Citations (PDF) |
| 380 | Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathyBrain, 2018, 141, 3377-3388 | 8.4 | 41 | Citations (PDF) |
| 381 | Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result | 4.0 | 33 | Citations (PDF) |
| 382 | Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project | 2.5 | 74 | Citations (PDF) |
| 383 | Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia | 6.6 | 186 | Citations (PDF) |
| 384 | Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study | 4.0 | 93 | Citations (PDF) |
| 385 | Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive declineBrain, 2018, 141, 3443-3456 | 8.4 | 140 | Citations (PDF) |
| 386 | IC‐P‐187: CORTICAL T1‐W/T2‐W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS | 0.5 | 0 | Citations (PDF) |
| 387 | Clinical phenotype, atrophy, and small vessel disease in
<i>APOE</i>
ε2 carriers with Alzheimer disease | 1.0 | 54 | Citations (PDF) |
| 388 | Plasma Amyloid as Prescreener for the Earliest <scp>A</scp>lzheimer Pathological Changes | 6.6 | 291 | Citations (PDF) |
| 389 | Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease | 3.3 | 29 | Citations (PDF) |
| 390 | Disease Course Varies According to Age and Symptom Length in Alzheimer’s Disease | 2.6 | 29 | Citations (PDF) |
| 391 | Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review | 6.6 | 54 | Citations (PDF) |
| 392 | Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia | 6.6 | 26 | Citations (PDF) |
| 393 | Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals | 3.8 | 31 | Citations (PDF) |
| 394 | Amsterdam Dementia Cohort: Performing Research to Optimize Care | 2.6 | 317 | Citations (PDF) |
| 395 | Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease | 6.6 | 26 | Citations (PDF) |
| 396 | Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier | 4.0 | 40 | Citations (PDF) |
| 397 | Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults | 4.0 | 33 | Citations (PDF) |
| 398 | Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease | 6.6 | 120 | Citations (PDF) |
| 399 | Evaluating combinations of diagnostic tests to discriminate different dementia types | 2.5 | 23 | Citations (PDF) |
| 400 | Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change | 2.9 | 25 | Citations (PDF) |
| 401 | Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression | 2.6 | 19 | Citations (PDF) |
| 402 | Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results | 6.6 | 112 | Citations (PDF) |
| 403 | Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort | 17.6 | 132 | Citations (PDF) |
| 404 | Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease | 3.0 | 59 | Citations (PDF) |
| 405 | A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease | 2.6 | 57 | Citations (PDF) |
| 406 | White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β | 2.6 | 21 | Citations (PDF) |
| 407 | Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly | 2.6 | 75 | Citations (PDF) |
| 408 | Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests | 2.6 | 23 | Citations (PDF) |
| 409 | Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design | 2.5 | 62 | Citations (PDF) |
| 410 | Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations | 3.4 | 126 | Citations (PDF) |
| 411 | Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies | 6.3 | 136 | Citations (PDF) |
| 412 | Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study | 3.5 | 85 | Citations (PDF) |
| 413 | Quantification of Tau Load Using [18F]AV1451 PET | 2.2 | 46 | Citations (PDF) |
| 414 | CSF ApoE predicts clinical progression in nondemented APOEε4 carriers | 3.4 | 27 | Citations (PDF) |
| 415 | The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group | 6.6 | 84 | Citations (PDF) |
| 416 | Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values | 2.5 | 24 | Citations (PDF) |
| 417 | Rare Genetic Variant in
SORL1
May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of
APOE
-
ɛ
4 Homozygosity | 2.6 | 38 | Citations (PDF) |
| 418 | The blood brain barrier in Alzheimer’s disease | 2.5 | 104 | Citations (PDF) |
| 419 | Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting | 3.3 | 44 | Citations (PDF) |
| 420 | A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease | 3.5 | 70 | Citations (PDF) |
| 421 | Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia | 2.5 | 22 | Citations (PDF) |
| 422 | Alzheimer’s disease: The state of the art in resting-state magnetoencephalography | 1.3 | 94 | Citations (PDF) |
| 423 | Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy | 3.0 | 132 | Citations (PDF) |
| 424 | Consensus guidelines for lumbar puncture in patients with neurological diseases | 2.5 | 254 | Citations (PDF) |
| 425 | Selective impairment of hippocampus and posterior hub areas in Alzheimer’s disease: an MEG-based multiplex network studyBrain, 2017, 140, 1466-1485 | 8.4 | 166 | Citations (PDF) |
| 426 | Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects | 6.6 | 24 | Citations (PDF) |
| 427 | The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria | 2.6 | 53 | Citations (PDF) |
| 428 | Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project | 17.6 | 88 | Citations (PDF) |
| 429 | A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease | 3.4 | 58 | Citations (PDF) |
| 430 | [IC‐P‐130]: MRI‐BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY | 0.5 | 0 | Citations (PDF) |
| 431 | [P1–392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA | 0.5 | 0 | Citations (PDF) |
| 432 | Blood‐based metabolic signatures in Alzheimer's disease | 2.5 | 76 | Citations (PDF) |
| 433 | Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study | 3.3 | 45 | Citations (PDF) |
| 434 | Lumbar puncture in patients with neurologic conditions | 2.5 | 12 | Citations (PDF) |
| 435 | Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two‐dimensional phase‐contrast magnetic resonance imaging | 2.5 | 46 | Citations (PDF) |
| 436 | EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects | 3.4 | 137 | Citations (PDF) |
| 437 | Diagnostic impact of [18F]flutemetamol PET in early-onset dementia | 6.6 | 113 | Citations (PDF) |
| 438 | Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies | 3.4 | 12 | Citations (PDF) |
| 439 | A novel CCM2 variant in a family with non‐progressive cognitive complaints and cerebral microbleeds | 1.5 | 6 | Citations (PDF) |
| 440 | [P1–243]: ALPHA‐SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES | 0.5 | 2 | Citations (PDF) |
| 441 | [P1–009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB‐BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS | 0.5 | 0 | Citations (PDF) |
| 442 | [P2–473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 443 | [P3–161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL Aβ CLEARANCE? | 0.5 | 0 | Citations (PDF) |
| 444 | [P3–226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER's DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES | 0.5 | 0 | Citations (PDF) |
| 445 | [P3–375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT | 0.5 | 0 | Citations (PDF) |
| 446 | [P3–386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI | 0.5 | 1 | Citations (PDF) |
| 447 | [P3–407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 448 | [P3–422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA | 0.5 | 0 | Citations (PDF) |
| 449 | [P3–566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 450 | [P4–219]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 451 | [P4–235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR | 0.5 | 0 | Citations (PDF) |
| 452 | [IC‐P‐005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID‐β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS | 0.5 | 1 | Citations (PDF) |
| 453 | [IC‐P‐037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE | 0.5 | 1 | Citations (PDF) |
| 454 | [IC‐P‐055]: EFFECT OF APOE‐ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 455 | [IC‐P‐085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT | 0.5 | 0 | Citations (PDF) |
| 456 | [IC‐P‐095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 457 | [IC‐P‐106]: PREDICTING PROGRESSION IN PRE‐DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE | 0.5 | 0 | Citations (PDF) |
| 458 | [IC‐P‐110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 459 | [IC‐P‐203]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 460 | [IC‐P‐206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR | 0.5 | 0 | Citations (PDF) |
| 461 | [TD‐P‐020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 462 | [P1–250]: DECISION TREE ANALYSIS REVEALS TWO CUT‐OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS | 0.5 | 0 | Citations (PDF) |
| 463 | [P1–326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEB‐BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS | 0.5 | 0 | Citations (PDF) |
| 464 | [P1–375]: DATA‐DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY | 0.5 | 2 | Citations (PDF) |
| 465 | [P1–440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 466 | [P1–486]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEART‐BRAIN CONNECTION STUDY | 0.5 | 0 | Citations (PDF) |
| 467 | [P2–052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH | 0.5 | 3 | Citations (PDF) |
| 468 | [P2–207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID‐β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS | 0.5 | 0 | Citations (PDF) |
| 469 | [P2–242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES | 0.5 | 0 | Citations (PDF) |
| 470 | [P2–249]: CONTACTIN‐1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NON‐DEMENTED CONTROLS | 0.5 | 0 | Citations (PDF) |
| 471 | [P2–335]: EFFECT OF APOE ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 472 | [F1–03–04]: BIOMARKER‐BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE | 0.5 | 0 | Citations (PDF) |
| 473 | [O1–01–02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 474 | [O1–05–03]: CSF AMYLOID BETA 1–42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS‐DEPENDENT UPWARD DRIFT | 0.5 | 0 | Citations (PDF) |
| 475 | [O1–05–04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER's DISEASE: AN ASSAY COMPARISON STUDY | 0.5 | 0 | Citations (PDF) |
| 476 | [O2–01–01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) | 0.5 | 0 | Citations (PDF) |
| 477 | [O2–10–06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM | 0.5 | 0 | Citations (PDF) |
| 478 | [O2–11–03]: PREDICTING PROGRESSION IN PRE‐DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE | 0.5 | 0 | Citations (PDF) |
| 479 | [O2–12–03]: DURATION OF ALZHEIMER's DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTI‐STATE MODEL ANALYSIS | 0.5 | 7 | Citations (PDF) |
| 480 | [O3–06–04]: PROMINENT NON‐MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION | 0.5 | 0 | Citations (PDF) |
| 481 | [P4–525]: DATA‐DRIVEN TAU‐PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE | 0.5 | 1 | Citations (PDF) |
| 482 | [DT‐01–02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT | 0.5 | 0 | Citations (PDF) |
| 483 | [P3–075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS | 0.5 | 0 | Citations (PDF) |
| 484 | 294Long-term prognosis of silent myocardial infarction detected by LGE-CMR in patients presenting with first acute myocardial infarction | 2.2 | 1 | Citations (PDF) |
| 485 | MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis | 4.0 | 95 | Citations (PDF) |
| 486 | Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment | 6.6 | 30 | Citations (PDF) |
| 487 | Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline | 6.6 | 54 | Citations (PDF) |
| 488 | Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS) | 1.8 | 18 | Citations (PDF) |
| 489 | Subjective Memory Complaints in
APOE
ɛ
4 Carriers are Associated with High Amyloid-β Burden | 2.6 | 51 | Citations (PDF) |
| 490 | Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers | 2.6 | 17 | Citations (PDF) |
| 491 | Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology | 2.6 | 46 | Citations (PDF) |
| 492 | Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid | 2.6 | 5 | Citations (PDF) |
| 493 | Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer’s Disease. An MEG Study with Virtual Electrodes | 2.3 | 94 | Citations (PDF) |
| 494 | Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease | 8.7 | 72 | Citations (PDF) |
| 495 | A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands | 1.9 | 19 | Citations (PDF) |
| 496 | Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer’s Disease | 2.6 | 43 | Citations (PDF) |
| 497 | P1‐297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients 2016, 12, | | 0 | Citations (PDF) |
| 498 | Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline | 2.5 | 52 | Citations (PDF) |
| 499 | IC‐03‐02: Grey Matter Connectivity is Associated with Clinical Progression in Non‐Demented, Amyloid Positive Patients 2016, 12, | | 0 | Citations (PDF) |
| 500 | P2‐221: Cerebral Blood Flow Measured with Phase‐Contrast MRI in AD, MCI and Controls | 0.5 | 0 | Citations (PDF) |
| 501 | IC‐P‐196: Quantification of TAU Load Using [18F]AV‐1451 and PET | 0.5 | 0 | Citations (PDF) |
| 502 | P4‐179: MEG Cross‐Frequency Analysis in Patients With Alzheimer’s Disease 2016, 12, | | 5 | Citations (PDF) |
| 503 | O3‐08‐01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status | 0.5 | 0 | Citations (PDF) |
| 504 | P1‐178: Impact of Co‐Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders | 0.5 | 0 | Citations (PDF) |
| 505 | IC‐03‐05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer’s Disease And Controls 2016, 12, | | 1 | Citations (PDF) |
| 506 | P1‐284: Grey Matter Connectivity is Associated With Clinical Progression in Non‐Demented, Amyloid Positive Patients | 0.5 | 0 | Citations (PDF) |
| 507 | P1‐327: Cross‐Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease 2016, 12, | | 0 | Citations (PDF) |
| 508 | IC‐P‐097: A Novel Neuroimaging Approach to Capture Cognitive Reserve | 0.5 | 0 | Citations (PDF) |
| 509 | IC‐P‐103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non‐Demented Stages of Alzheimer’s Disease | 0.5 | 0 | Citations (PDF) |
| 510 | IC‐P‐106: Cross‐Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease | 0.5 | 0 | Citations (PDF) |
| 511 | IC‐P‐108: Cerebral Blood Flow Measured With Phase‐Contrast MRI in AD, MCI and Controls | 0.5 | 0 | Citations (PDF) |
| 512 | P2‐348: Impact of Non‐Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials | 0.5 | 0 | Citations (PDF) |
| 513 | P2‐282: EEG‐Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls | 0.5 | 0 | Citations (PDF) |
| 514 | IC‐P‐147: Atrophy Patterns Predicting Cognitive Decline in Non‐Demented Subjects are Independent of Amyloid Pathology | 0.5 | 0 | Citations (PDF) |
| 515 | P3‐144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts | 0.5 | 0 | Citations (PDF) |
| 516 | P4‐112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non‐Demented Elderly | 0.5 | 0 | Citations (PDF) |
| 517 | P4‐153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Non‐AD in Memory Clinic and Community‐Based Cohorts | 0.5 | 1 | Citations (PDF) |
| 518 | P4‐191: A Novel Neuroimaging Approach to Capture Cognitive Reserve | 0.5 | 0 | Citations (PDF) |
| 519 | P4‐215: Quantification of Tau Load Using [18F]AV‐1451 and Pet | 0.5 | 0 | Citations (PDF) |
| 520 | P4‐224: Alzheimer’s Disease Patients With Osas History Have Higher CSF Tau Levels | 0.5 | 3 | Citations (PDF) |
| 521 | P4‐240: Deciding About Diagnostic Testing for Alzheimer’s Disease: Patients’ Views and Experiences | 0.5 | 0 | Citations (PDF) |
| 522 | O1‐01‐01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non‐Demented Stages of Alzheimer’s Disease 2016, 12, | | 0 | Citations (PDF) |
| 523 | O1‐05‐02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU | 0.5 | 0 | Citations (PDF) |
| 524 | O4‐02‐04: Atrophy Patterns Predicting Cognitive Decline in Non‐Demented Subjects are Independent of Amyloid Pathology | 0.5 | 0 | Citations (PDF) |
| 525 | O4‐09‐04: Towards Data‐Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases 2016, 12, | | 0 | Citations (PDF) |
| 526 | P1‐174: Cost‐Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach | 0.5 | 0 | Citations (PDF) |
| 527 | Combinations of Service Use Types of People With Early Cognitive Disorders | 2.4 | 10 | Citations (PDF) |
| 528 | Differential diagnosis of neurodegenerative diseases using structural MRI data | 3.3 | 182 | Citations (PDF) |
| 529 | Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort | 2.6 | 105 | Citations (PDF) |
| 530 | Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults | 2.9 | 38 | Citations (PDF) |
| 531 | P1‐418: Clinicians’ Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimer’s Disease 2016, 12, | | 0 | Citations (PDF) |
| 532 | P2‐335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples | 0.5 | 0 | Citations (PDF) |
| 533 | P2‐342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function | 0.5 | 0 | Citations (PDF) |
| 534 | O5‐07‐02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic 2016, 12, | | 1 | Citations (PDF) |
| 535 | ABCA7 p.G215S as potential protective factor for Alzheimer's disease | 3.4 | 50 | Citations (PDF) |
| 536 | Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease | 3.5 | 58 | Citations (PDF) |
| 537 | Cortical phase changes measured using 7‐T MRI in subjects with subjective cognitive impairment, and their association with cognitive function | 2.4 | 14 | Citations (PDF) |
| 538 | Suspected non-Alzheimer disease pathophysiology — concept and controversy | 28.6 | 276 | Citations (PDF) |
| 539 | The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials | 11.6 | 533 | Citations (PDF) |
| 540 | Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis | 8.7 | 88 | Citations (PDF) |
| 541 | Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases | 3.4 | 88 | Citations (PDF) |
| 542 | Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease | 3.4 | 48 | Citations (PDF) |
| 543 | EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls | 3.4 | 57 | Citations (PDF) |
| 544 | Gray matter network disruptions and amyloid beta in cognitively normal adults | 3.4 | 57 | Citations (PDF) |
| 545 | Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease | 6.3 | 113 | Citations (PDF) |
| 546 | The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis | 6.3 | 102 | Citations (PDF) |
| 547 | Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment | 7.8 | 116 | Citations (PDF) |
| 548 | Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease | 3.6 | 109 | Citations (PDF) |
| 549 | Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s diseaseBrain, 2016, 139, 2528-2539 | 8.4 | 69 | Citations (PDF) |
| 550 | O4‐05‐04: A four‐center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients 2015, 11, | | 0 | Citations (PDF) |
| 551 | Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes | 2.5 | 85 | Citations (PDF) |
| 552 | IC‐02‐03: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease 2015, 11, | | 0 | Citations (PDF) |
| 553 | Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer’s Disease | 2.6 | 39 | Citations (PDF) |
| 554 | Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies | 2.6 | 396 | Citations (PDF) |
| 555 | Matrix Metalloproteinases in Alzheimer’s Disease and Concurrent Cerebral Microbleeds | 2.6 | 86 | Citations (PDF) |
| 556 | Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease | 2.6 | 61 | Citations (PDF) |
| 557 | Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease | 2.6 | 50 | Citations (PDF) |
| 558 | More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease | 2.6 | 52 | Citations (PDF) |
| 559 | Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer’s Disease | 2.6 | 13 | Citations (PDF) |
| 560 | O3‐09‐02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions? 2015, 11, | | 0 | Citations (PDF) |
| 561 | O4‐11‐04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study 2015, 11, | | 1 | Citations (PDF) |
| 562 | Loss of EEGNetwork Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies | 4.6 | 76 | Citations (PDF) |
| 563 | Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease | 2.3 | 75 | Citations (PDF) |
| 564 | Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease | 3.5 | 227 | Citations (PDF) |
| 565 | O2‐02‐06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment 2015, 11, | | 0 | Citations (PDF) |
| 566 | Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study | 3.3 | 45 | Citations (PDF) |
| 567 | F2‐03‐03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease 2015, 11, | | 0 | Citations (PDF) |
| 568 | IC‐01‐04: Diagnostic impact of [18F]flutemetamol amyloid imaging in young‐onset dementia 2015, 11, | | 2 | Citations (PDF) |
| 569 | O1‐07‐02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset | 0.5 | 0 | Citations (PDF) |
| 570 | F2‐03‐02: Early onset APOE‐ɛ4‐negative Alzheimer's disease patients show faster cognitive decline on non‐memory domains 2015, 11, | | 1 | Citations (PDF) |
| 571 | F2‐03‐04: Genetic risk factors for posterior cortical atrophy 2015, 11, | | 2 | Citations (PDF) |
| 572 | O3‐14‐02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool 2015, 11, | | 0 | Citations (PDF) |
| 573 | O3‐14‐04: The relation between eeg spectral analysis and clinical progression in non‐demented, amyloid‐positive subjects | 0.5 | 1 | Citations (PDF) |
| 574 | F4‐02‐02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors 2015, 11, | | 0 | Citations (PDF) |
| 575 | O5‐02‐03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression 2015, 11, | | 0 | Citations (PDF) |
| 576 | O5‐05‐03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease 2015, 11, | | 0 | Citations (PDF) |
| 577 | The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease | 3.4 | 27 | Citations (PDF) |
| 578 | Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge | 4.4 | 316 | Citations (PDF) |
| 579 | Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stageBrain, 2015, 138, 1327-1338 | 8.4 | 349 | Citations (PDF) |
| 580 | Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease | 3.4 | 62 | Citations (PDF) |
| 581 | Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjectsBrain, 2015, 138, 2701-2715 | 8.4 | 119 | Citations (PDF) |
| 582 | The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological featuresBrain, 2015, 138, 2732-2749 | 8.4 | 478 | Citations (PDF) |
| 583 | Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? | 3.6 | 94 | Citations (PDF) |
| 584 | The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis | 2.1 | 24 | Citations (PDF) |
| 585 | Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains | 1.0 | 55 | Citations (PDF) |
| 586 | Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy | 2.6 | 18 | Citations (PDF) |
| 587 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia | 16.6 | 1,474 | Citations (PDF) |
| 588 | Prevalence of Amyloid PET Positivity in Dementia Syndromes | 16.6 | 609 | Citations (PDF) |
| 589 | Mild cognitive impairment with suspected nonamyloid pathology (SNAP) | 1.0 | 132 | Citations (PDF) |
| 590 | The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia | 1.3 | 50 | Citations (PDF) |
| 591 | Microbleeds, Mortality, and Stroke in Alzheimer Disease | 17.6 | 59 | Citations (PDF) |
| 592 | Standard biobanking conditions prevent evaporation of body fluid samples | 1.5 | 13 | Citations (PDF) |
| 593 | Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort | 6.6 | 128 | Citations (PDF) |
| 594 | Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study | 1.9 | 169 | Citations (PDF) |
| 595 | Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach | 1.7 | 30 | Citations (PDF) |
| 596 | Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage | 6.0 | 69 | Citations (PDF) |
| 597 | Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease | 17.6 | 226 | Citations (PDF) |
| 598 | 7T T2∗-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease | 3.4 | 48 | Citations (PDF) |
| 599 | Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study | 1.3 | 26 | Citations (PDF) |
| 600 | Cerebral perfusion in the predementia stages of Alzheimer’s disease | 3.6 | 128 | Citations (PDF) |
| 601 | Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease | 2.3 | 66 | Citations (PDF) |
| 602 | SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease | 2.9 | 46 | Citations (PDF) |
| 603 | Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease | 2.5 | 76 | Citations (PDF) |
| 604 | Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort | 3.4 | 16 | Citations (PDF) |
| 605 | The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia | 2.0 | 42 | Citations (PDF) |
| 606 | Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies | 2.9 | 211 | Citations (PDF) |
| 607 | Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions | 1.0 | 55 | Citations (PDF) |
| 608 | Prevalence of cortical superficial siderosis in a memory clinic population | 1.0 | 72 | Citations (PDF) |
| 609 | PL‐02‐02: PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE 2014, 10, | | 0 | Citations (PDF) |
| 610 | Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging | 8.7 | 76 | Citations (PDF) |
| 611 | Amyloid and its association with default network integrity in Alzheimer's disease | 3.5 | 40 | Citations (PDF) |
| 612 | Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease | 3.4 | 33 | Citations (PDF) |
| 613 | O3‐06‐02: A RE‐EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS 2014, 10, | | 0 | Citations (PDF) |
| 614 | Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers | 17.6 | 151 | Citations (PDF) |
| 615 | Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement | 3.5 | 36 | Citations (PDF) |
| 616 | The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer’s disease | 5.5 | 7 | Citations (PDF) |
| 617 | Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study | 3.4 | 17 | Citations (PDF) |
| 618 | The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease | 6.6 | 72 | Citations (PDF) |
| 619 | Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology | 5.0 | 27 | Citations (PDF) |
| 620 | The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment | 2.6 | 50 | Citations (PDF) |
| 621 | Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers | 3.5 | 125 | Citations (PDF) |
| 622 | Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images | 5.5 | 30 | Citations (PDF) |
| 623 | Distinct perfusion patterns in Alzheimer’s disease, frontotemporal dementia and dementia with Lewy bodies | 3.6 | 56 | Citations (PDF) |
| 624 | The structure of the geriatric depressed brain and response to electroconvulsive therapy | 1.8 | 26 | Citations (PDF) |
| 625 | Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population | 2.4 | 18 | Citations (PDF) |
| 626 | Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms | 2.6 | 19 | Citations (PDF) |
| 627 | Optimizing Patient Care and Research: The Amsterdam Dementia Cohort | 2.6 | 354 | Citations (PDF) |
| 628 | Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort | 2.6 | 116 | Citations (PDF) |
| 629 | The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease | 2.6 | 38 | Citations (PDF) |
| 630 | P1‐258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION 2014, 10, | | 1 | Citations (PDF) |
| 631 | O2‐13‐05: APOLIPOPROTEIN A‐1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD 2014, 10, | | 0 | Citations (PDF) |
| 632 | O5‐02‐02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY 2014, 10, | | 0 | Citations (PDF) |
| 633 | P1‐135: DIRECTED ANTERIOR‐TO‐POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS 2014, 10, | | 1 | Citations (PDF) |
| 634 | O2‐13‐03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA 2014, 10, | | 0 | Citations (PDF) |
| 635 | P1‐223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 636 | IC‐P‐009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN 2014, 10, | | 0 | Citations (PDF) |
| 637 | IC‐P‐085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 638 | O4‐01‐05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS 2014, 10, | | 1 | Citations (PDF) |
| 639 | P1‐015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE‐BASED MICROARRAY PLATFORM 2014, 10, | | 0 | Citations (PDF) |
| 640 | P1‐385: RATIONALE AND DESIGN OF THE NL‐ENIGMA STUDY, A DUTCH 24‐WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 641 | O2‐07‐04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS 2014, 10, | | 0 | Citations (PDF) |
| 642 | IC‐P‐077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY 2014, 10, | | 0 | Citations (PDF) |
| 643 | O4‐01‐06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN 2014, 10, | | 0 | Citations (PDF) |
| 644 | IC‐P‐013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA 2014, 10, | | 3 | Citations (PDF) |
| 645 | IC‐P‐076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS 2014, 10, | | 1 | Citations (PDF) |
| 646 | O2‐14‐03: THE REST‐ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY‐ONSET DEMENTIA 2014, 10, | | 0 | Citations (PDF) |
| 647 | IC‐P‐056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 648 | IC‐P‐109: RATIONALE AND DESIGN OF THE NL‐ENIGMA STUDY: A DUTCH 24‐WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE 2014, 10, | | 1 | Citations (PDF) |
| 649 | P1‐134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES 2014, 10, | | 0 | Citations (PDF) |
| 650 | P1‐149: CSF VILIP‐1 AND YKL‐40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 651 | P4‐273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE 2014, 10, | | 0 | Citations (PDF) |
| 652 | O1‐02‐04: 7T T2*‐WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY‐ AND LATE‐ONSET AD 2014, 10, | | 0 | Citations (PDF) |
| 653 | O4‐01‐01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA 2014, 10, | | 1 | Citations (PDF) |
| 654 | P3‐096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART 2014, 10, | | 1 | Citations (PDF) |
| 655 | P1‐174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME 2014, 10, | | 0 | Citations (PDF) |
| 656 | P1‐415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT 2014, 10, | | 0 | Citations (PDF) |
| 657 | Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer¿s disease correlates with pathology | 5.0 | 18 | Citations (PDF) |
| 658 | Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity | 3.4 | 24 | Citations (PDF) |
| 659 | Frontotemporale dementie en de psychiatrische differentiaaldiagnose: twee gevalsbeschrijvingen en de rationale van de ‘Laat Ontstaan Frontaal syndroom (LOF)-studie’ | 0.0 | 0 | Citations (PDF) |
| 660 | Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study | 3.4 | 158 | Citations (PDF) |
| 661 | S1–02–02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's‐type dementia 2013, 9, | | 0 | Citations (PDF) |
| 662 | O3–05–01: Physical activity, independent functioning and emotional well‐being in early‐onset dementia 2013, 9, | | 0 | Citations (PDF) |
| 663 | Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease | 3.4 | 183 | Citations (PDF) |
| 664 | O1–09–01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting 2013, 9, | | 0 | Citations (PDF) |
| 665 | Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease | 3.4 | 72 | Citations (PDF) |
| 666 | F5–01–02: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints 2013, 9, | | 1 | Citations (PDF) |
| 667 | Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI | 1.0 | 126 | Citations (PDF) |
| 668 | Alzheimer's disease: connecting findings from graph theoretical studies of brain networks | 3.4 | 404 | Citations (PDF) |
| 669 | Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity | 8.7 | 239 | Citations (PDF) |
| 670 | Differential effect of
APOE
genotype on amyloid load and glucose metabolism in AD dementia | 1.0 | 111 | Citations (PDF) |
| 671 | Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease | 1.0 | 176 | Citations (PDF) |
| 672 | Preclinical AD predicts decline in memory and executive functions in subjective complaints | 1.0 | 134 | Citations (PDF) |
| 673 | Cerebral atrophy in elderly with subjective memory complaints | 3.4 | 9 | Citations (PDF) |
| 674 | Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease | 2.6 | 22 | Citations (PDF) |
| 675 | Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population | 2.6 | 21 | Citations (PDF) |
| 676 | Progression to dementia in memory clinic patients without dementia | 1.0 | 24 | Citations (PDF) |
| 677 | Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ε4 Carriers | 2.6 | 21 | Citations (PDF) |
| 678 | Single-Subject Grey Matter Graphs in Alzheimer's Disease | 2.3 | 119 | Citations (PDF) |
| 679 | Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage | 4.0 | 182 | Citations (PDF) |
| 680 | Quantitative regional validation of the visual rating scale for posterior cortical atrophy | 3.6 | 31 | Citations (PDF) |
| 681 | Injury markers predict time to dementia in subjects with MCI and amyloid pathology | 1.0 | 136 | Citations (PDF) |
| 682 | Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort | 1.0 | 286 | Citations (PDF) |
| 683 | Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvementBrain, 2012, 135, 2115-2125 | 8.4 | 116 | Citations (PDF) |
| 684 | Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile | 2.6 | 168 | Citations (PDF) |
| 685 | Blood–brain barrier P-glycoprotein function in Alzheimer's diseaseBrain, 2012, 135, 181-189 | 8.4 | 284 | Citations (PDF) |
| 686 | White Matter Lesion Progression in LADIS | 6.0 | 96 | Citations (PDF) |
| 687 | Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease | 2.6 | 77 | Citations (PDF) |
| 688 | Age and diagnostic performance of Alzheimer disease CSF biomarkers | 1.0 | 159 | Citations (PDF) |
| 689 | Microbleeds in vascular dementia: Clinical aspects | 3.7 | 50 | Citations (PDF) |
| 690 | S2‐02‐01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE | 0.5 | 0 | Citations (PDF) |
| 691 | O4‐03‐01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease | 0.5 | 0 | Citations (PDF) |
| 692 | Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples | 2.3 | 25 | Citations (PDF) |
| 693 | Microglial activation in healthy aging | 3.4 | 141 | Citations (PDF) |
| 694 | Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers | 3.4 | 58 | Citations (PDF) |
| 695 | Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment | 3.4 | 375 | Citations (PDF) |
| 696 | Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics | 3.4 | 37 | Citations (PDF) |
| 697 | Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease | 3.4 | 57 | Citations (PDF) |
| 698 | Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI | 3.4 | 78 | Citations (PDF) |
| 699 | Microbleeds do not affect rate of cognitive decline in Alzheimer disease | 1.0 | 74 | Citations (PDF) |
| 700 | Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia | 6.3 | 28 | Citations (PDF) |
| 701 | Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia | 2.1 | 27 | Citations (PDF) |
| 702 | Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography? | 2.5 | 93 | Citations (PDF) |
| 703 | Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease | 4.4 | 218 | Citations (PDF) |
| 704 | Clinical aspects of microbleeds in Alzheimer's disease | 2.1 | 20 | Citations (PDF) |
| 705 | Brain atrophy accelerates cognitive decline in cerebral small vessel disease | 1.0 | 136 | Citations (PDF) |
| 706 | Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET | 5.5 | 151 | Citations (PDF) |
| 707 | Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study | 3.4 | 36 | Citations (PDF) |
| 708 | Brain microbleeds and Alzheimer’s disease: innocent observation or key player?Brain, 2011, 134, 335-344 | 8.4 | 311 | Citations (PDF) |
| 709 | Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations | 6.3 | 695 | Citations (PDF) |
| 710 | Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort | 2.1 | 62 | Citations (PDF) |
| 711 | Progression from MCI to AD: Predictive value of CSF Aβ42 is modified by APOE genotype | 3.4 | 13 | Citations (PDF) |
| 712 | F1‐01‐01: Early‐onset versus late‐onset Alzheimer's disease: A role for APOE e4? 2011, 7, | | 0 | Citations (PDF) |
| 713 | Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values | 2.6 | 22 | Citations (PDF) |
| 714 | Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele | 17.9 | 295 | Citations (PDF) |
| 715 | Visual assessment of posterior atrophy development of a MRI rating scale | 3.6 | 372 | Citations (PDF) |
| 716 | Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging | 6.0 | 129 | Citations (PDF) |
| 717 | Incident lacunes influence cognitive decline | 1.0 | 199 | Citations (PDF) |
| 718 | Tau and p-tau as CSF biomarkers in dementia: a meta-analysis | 2.3 | 152 | Citations (PDF) |
| 719 | EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity | 6.3 | 47 | Citations (PDF) |
| 720 | Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease | 2.6 | 35 | Citations (PDF) |
| 721 | Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives | 2.6 | 17 | Citations (PDF) |
| 722 | Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI | 1.3 | 21 | Citations (PDF) |
| 723 | Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease | 1.1 | 332 | Citations (PDF) |
| 724 | Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study | 6.0 | 86 | Citations (PDF) |
| 725 | Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease | 6.3 | 112 | Citations (PDF) |
| 726 | Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects | 2.6 | 39 | Citations (PDF) |
| 727 | Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study | 3.4 | 96 | Citations (PDF) |
| 728 | Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images | 6.3 | 57 | Citations (PDF) |
| 729 | Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone | 2.6 | 416 | Citations (PDF) |
| 730 | BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology | 2.6 | 82 | Citations (PDF) |
| 731 | CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease | 2.6 | 87 | Citations (PDF) |
| 732 | CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age | 2.6 | 47 | Citations (PDF) |
| 733 | Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study | 6.3 | 108 | Citations (PDF) |
| 734 | Relationship of Cerebrospinal Fluid Markers to 11 C-PiB and 18 F-FDDNP Binding | 5.5 | 163 | Citations (PDF) |
| 735 | Detection of Alzheimer Pathology In Vivo Using Both 11 C-PIB and 18 F-FDDNP PET | 5.5 | 122 | Citations (PDF) |
| 736 | Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64–Detector Row CT | 8.7 | 133 | Citations (PDF) |
| 737 | MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population | 6.0 | 127 | Citations (PDF) |
| 738 | CSF biomarkers in relationship to cognitive profiles in Alzheimer disease | 1.0 | 103 | Citations (PDF) |
| 739 | A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease | 1.7 | 161 | Citations (PDF) |
| 740 | CSF biomarkers predict rate of cognitive decline in Alzheimer disease | 1.0 | 139 | Citations (PDF) |
| 741 | Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease | 1.0 | 75 | Citations (PDF) |
| 742 | Differential association of [
11
C]PIB and [
18
F]FDDNP binding with cognitive impairment | 1.0 | 45 | Citations (PDF) |
| 743 | Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory | 2.1 | 354 | Citations (PDF) |
| 744 | Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion‐weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the elderly) study | 3.4 | 35 | Citations (PDF) |
| 745 | Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data | 3.1 | 6 | Citations (PDF) |
| 746 | Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease | 3.6 | 95 | Citations (PDF) |
| 747 | Patients With Alzheimer Disease With Multiple Microbleeds | 6.0 | 207 | Citations (PDF) |
| 748 | Progression of Mild Cognitive Impairment to Dementia | 6.0 | 134 | Citations (PDF) |
| 749 | CSF biomarker levels in early and late onset Alzheimer's disease | 3.4 | 130 | Citations (PDF) |
| 750 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment | 16.6 | 1,052 | Citations (PDF) |
| 751 | Small vessel versus large vessel vascular dementia | 3.4 | 57 | Citations (PDF) |
| 752 | Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease | 2.2 | 37 | Citations (PDF) |
| 753 | De diagnostische waarde van de Visuele Associatie Test (vat) in een geheugenpoliklinieksetting | 0.0 | 0 | Citations (PDF) |
| 754 | Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance | 2.3 | 43 | Citations (PDF) |
| 755 | Global dynamical analysis of the EEG in Alzheimer’s disease: Frequency-specific changes of functional interactions | 1.3 | 99 | Citations (PDF) |
| 756 | Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration | 1.3 | 55 | Citations (PDF) |
| 757 | EEG functional connectivity and ApoE genotype in Alzheimer’s disease and controls | 1.3 | 28 | Citations (PDF) |
| 758 | Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study | 2.1 | 131 | Citations (PDF) |
| 759 | CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease | 3.4 | 104 | Citations (PDF) |
| 760 | Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathologyBrain, 2008, 131, 3286-3298 | 8.4 | 276 | Citations (PDF) |
| 761 | Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements | 2.3 | 16 | Citations (PDF) |
| 762 | The use of EEG in the diagnosis of dementia with Lewy bodies | 6.3 | 84 | Citations (PDF) |
| 763 | Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia | 6.0 | 82 | Citations (PDF) |
| 764 | Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period | 6.0 | 357 | Citations (PDF) |
| 765 | Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities | 2.6 | 75 | Citations (PDF) |
| 766 | Whole-brain atrophy rate in Alzheimer disease | 1.0 | 107 | Citations (PDF) |
| 767 | On the Etiology of Incident Brain Lacunes | 6.0 | 83 | Citations (PDF) |
| 768 | Brain magnetic resonance imaging abnormalities in patients with heart failure | 7.4 | 144 | Citations (PDF) |
| 769 | Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment | 1.0 | 81 | Citations (PDF) |
| 770 | The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia | 6.0 | 118 | Citations (PDF) |
| 771 | Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment | 6.8 | 74 | Citations (PDF) |
| 772 | Lobar Distribution of Changes in Gray Matter and White Matter in Memory Clinic Patients: Detected Using Magnetization Transfer Imaging | 2.6 | 20 | Citations (PDF) |
| 773 | Longitudinal changes of CSF biomarkers in memory clinic patients | 1.0 | 117 | Citations (PDF) |
| 774 | CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment | 3.4 | 165 | Citations (PDF) |
| 775 | Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study | 2.9 | 89 | Citations (PDF) |
| 776 | ASSOCIATION BETWEEN VITAMIN B 6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM | 2.9 | 10 | Citations (PDF) |
| 777 | Profile of Cognitive Impairment in Chronic Heart Failure | 2.9 | 176 | Citations (PDF) |
| 778 | Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI | 4.0 | 28 | Citations (PDF) |
| 779 | Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural MRI study | 2.1 | 282 | Citations (PDF) |
| 780 | White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study | 1.7 | 143 | Citations (PDF) |
| 781 | Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease | 3.4 | 30 | Citations (PDF) |
| 782 | Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study | 3.4 | 111 | Citations (PDF) |
| 783 | Infratentorial Abnormalities in Vascular Dementia | 6.0 | 32 | Citations (PDF) |
| 784 | Prevalence and severity of microbleeds in a memory clinic setting | 1.0 | 282 | Citations (PDF) |
| 785 | Hippocampal atrophy in Alzheimer disease: Age matters | 1.0 | 142 | Citations (PDF) |
| 786 | Usefulness of Longitudinal Measurements of β-Amyloid1–42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders | 1.1 | 16 | Citations (PDF) |
| 787 | The effect of
APOE
genotype on clinical phenotype in Alzheimer disease | 1.0 | 92 | Citations (PDF) |
| 788 | Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease | 6.3 | 182 | Citations (PDF) |
| 789 | Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia | 6.8 | 14 | Citations (PDF) |
| 790 | MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic | 2.2 | 34 | Citations (PDF) |
| 791 | Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study | 6.3 | 108 | Citations (PDF) |
| 792 | Epidemiology and risk factors of dementia | 6.3 | 460 | Citations (PDF) |
| 793 | Use of laboratory and imaging investigations in dementia | 6.3 | 12 | Citations (PDF) |
| 794 | Small Vessel Disease and General Cognitive Function in Nondisabled Elderly | 6.0 | 330 | Citations (PDF) |
| 795 | Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes | 3.4 | 161 | Citations (PDF) |
| 796 | Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease | 1.0 | 7 | Citations (PDF) |
| 797 | Cognitive decline in AD and mild cognitive impairment is associated with global brain damage | 1.0 | 67 | Citations (PDF) |
| 798 | Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease | 6.6 | 127 | Citations (PDF) |
| 799 | Frontal lobe damage and thalamic volume changes | 1.5 | 7 | Citations (PDF) |
| 800 | Title is missing! 0 | | 2 | Citations (PDF) |
| 801 | Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging: TAU-SPEX | 5.5 | 0 | Citations (PDF) |
| 802 | CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels | 8.4 | 0 | Citations (PDF) |
| 803 | Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease | 8.4 | 4 | Citations (PDF) |
| 804 | Cognitive and physical activities are associated with cognitive resilience in a memory clinic cohort | 3.6 | 0 | Citations (PDF) |
| 805 | The association between the MIND-NL diet, Dutch dietary guidelines, and global cognitive function in an older population at risk for cognitive decline | 3.1 | 0 | Citations (PDF) |
| 806 | Genetic testing of common and rare variants in dementia patients from a memory clinic | 6.6 | 0 | Citations (PDF) |
| 807 | General practitioners’ perspectives on blood biomarkers for Alzheimer's disease | 2.5 | 0 | Citations (PDF) |
| 808 | Opposing views or like-minded? International working group and Alzheimer’s association criteria | 8.4 | 0 | Citations (PDF) |
| 809 | Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease | 2.6 | 0 | Citations (PDF) |
| 810 | Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer’s disease | 14.1 | 0 | Citations (PDF) |
| 811 | The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts | 0.5 | 0 | Citations (PDF) |
| 812 | Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline | 6.6 | 0 | Citations (PDF) |
| 813 | Towards a Dutch nationwide registry for Alzheimer's disease and other dementia's: rationale, design, and initial observations of the ABOARD Cohort | 0.5 | 0 | Citations (PDF) |
| 814 | ‘Real‐world’ eligibility for anti‐amyloid treatment in a tertiary memory clinic setting | 0.5 | 0 | Citations (PDF) |
| 815 | Education, socioeconomic status, modifiable dementia risk and cognitive performance in older adults at risk of cognitive decline: a cross‐sectional study of the FINGER‐NL trial | 0.5 | 0 | Citations (PDF) |
| 816 | Women are less likely to be eligible for AD trials than men. | 0.5 | 0 | Citations (PDF) |
| 817 | Cognitive and neuroimaging trajectories in the behavioral variant of Alzheimer's disease | 0.5 | 0 | Citations (PDF) |
| 818 | Cerebrospinal fluid proteome alterations related to depressive symptoms in cognitive decline and Alzheimer's disease | 0.5 | 0 | Citations (PDF) |
| 819 | Distinct CSF lipidomic profiles are associated with five proteomic subtypes in patients with Alzheimer’s disease 0, 2, | | 0 | Citations (PDF) |
